#1COPYRIGHT © ABCELLERA BANK OF AMERICA TECHNOLOGY SOLUTIONS FOR DRUG DISCOVERY Carl Hansen, CEO SEPTEMBER 20, 2021 AbCellera#2BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 2 DISCLAIMER This presentation contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management's beliefs and assumptions and on information currently available to management. All statements contained in this presentation other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations. In some cases, you can identify forward-looking statements by the words "may," "will," "could," "would," "should," "expect," "intend," "plan,” “anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the Securities and Exchange Commission from time to time. We caution you that forward-looking statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. As a result, the forward-looking statements may not prove to be accurate. The forward-looking statements in this presentation represent our views as of the date hereof. We undertake no obligation to update any forward-looking statements for any reason, except as required by law.#3BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 3 ABCELLERA DRUG DISCOVERY FASTER, MORE EFFICIENT & MORE COST EFFECTIVE. Genito Urinary System Infectious Disease Autoimmune Diseases Allergic Inflammation Single Chain Antibodies (scFvs) CNS-Delivered Antiibodies Public Health Oncology Venture Capital IgGs, IgMs, IgAs THERAPEUTIC AREAS Equity MODALITIES PARTNER TYPES Private & Small Cap Biotech DEAL TYPES Royalties & Milestones ABCELLERA Neuro- degeneration Bispecific Antibodies Large & Mid Cap Biotech Option to Invest Global Pharma Other Pain Ophthalmology CAR-T Cell Conjugates Radioisotope Conjugates Women's Health Cardiovascular#4BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 4 THE PROBLEM LIMITED TECH & LIMITED ACCESS LIMITS IMPACT Drug developers focus on getting one drug candidate to the finish line. The result is a chronic underinvestment in the technologies to make the process of drug development better. Drug development fails too often, takes too long and costs too much. ~$3 billion + The average cost of drug development. ~9.4 to 12 years The time it takes an average antibody drug from initiation to approval. >90% failure rate#5BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 5 New technologies and a new business model are needed to lead antibody discovery and capture the antibody-based therapeutic market. +$118B 10.6% CAGR $143B 2019 $261B 2025 Antibody Market +$16B 59.6% CAGR $1B 2019 $17B 2025 Cell Therapy Market THE MARKET BREAKING BOTTLENECKS IN A $140B+ ANTIBODY THERAPEUTICS MARKET.#6BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 6 THE OPPORTUNITY UNLOCK THE NATURAL ANTIBODY DATABASE TO FIND NEW TREATMENTS. The immune system is a database that encodes nature's answers for fighting diseases and infections. But it's been challenging to access the database. Billions of unique antibodies inside each patient. Y > Each is made by single cell. O Finding the best antibody = finding the cell that makes it. Y Powered by over 500 million years of evolution. Antibodies created by natural immune systems benefit from selection, quality assurance and optimization. ~92% of approved antibody drugs are derived from natural immune systems.#7BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 7 REVITALIZE DRUG DISCOVERY WITH MODERN TECHNOLOGIES We believe our technology advantage comes from combining three things: Proprietary technologies that can generate massive multidimensional antibody datasets 2 | ** វ. Custom software to aggregate, store and maintain data 3 Artificial intelligence and powerful computational tools to extract actionable information from this data#8BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 8 SCOPE SCALE ENABLING TECHNOLOGY Data clouds (dots) generated at each step fuel and compound insights about antibodies, revealing rare ones with the desired qualities SOURCE immune response FROM ANY SPECIES Optimized Immunization FROM ANY SPECIES, ANY TARGET SEARCH millions OF IMMUNE CELLS High-Throughput Single-Cell Screening TO SEARCH IMMUNE CELLS Customizable Functional & Bead-Based Assays FIND hundreds OF UNIQUE ANTIBODIES WITH DESIRED PROPERTIES Automated Single- Cell Genomics + Repertoire Profiling PERFORMED IN PARALLEL Y DH Single-Cell & Immune Repertoire Sequencing ANALYZE dozens OF CANDIDATES WITH CHARACTERIZED PROPERTIES Customized Bioinformatics + Visualization OF SELECT CHAINS Lineage & Clonal Family Mapping ITERATIVE ENGINEER a few FULLY CHARACTERIZED & VALIDATED LEAD CANDIDATES High-Throughput Expression + Bioanalytics OF HIGH-CONFIDENCE PAIRED CHAINS US r 0000 1000 8000 Characterization & Validation DELIVER Lead Antibody Candidate(s) FOR DEVELOPMENT Y#9BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 9 FORWARD INTEGRATION TO ACCELERATE DRUG DEVELOPMENT ABCELLERA DEVELOPMENT Antibody Discovery TECH STACK x Preclinical Expansion into GMP/CMC manufacturing: PARTNER DEVELOPMENT Phase 1 MATPA FES Phase 2 Phase 3 & Approval AbCellera COMMERCIAL SALE#10BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 10 CENTRALIZATION TO DRIVE A FLYWHEEL OF CONTINUOUS LEARNING & DATA SCIENCE. increasing TECHNOLOGY ADVANTAGE more FACILITIES + TECHNOLOGY ACQUISITIONS more l more TEAM KNOW-HOW CAPABILITIES more ACCESS MULTI-DIMENSIONAL DATA GENERATION millions of IXTIX thousands of Y hundreds of thousands of smarter AL more OPPORTUNITIES more BUSINESS GROWTH more PARTNERSHIPS more DATA + LEARNING#11BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 11 HELP THE INDUSTRY & SHARE IN THE SUCCESS. target PARTNER BIOTECH, PHARMA ABCELLERA mAb Pre-clinical DISCOVERY RESEARCH FEES Near-term revenue from research payments (capital efficient) Phase 1 Phase 2 MILESTONES Phase 3 Approval Building a diversified portfolio of milestones & royalties (primary value driver) Multimillion dollar potential clinical and commercial milestone payments Commercial Sale ROYALTIES Majority of risk-adjusted value from royalty on commercial therapeutic sales#12BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 12 CREATE & CAPTURE VALUE WITH DEEPER POSITIONS Diverse deal structures provide the opportunity to deepen our position in successful molecules: Royalties & Milestones Option to Invest Equity / Equity-like#13BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 13 PARTNERING WITH DRUG DEVELOPERS OF ALL SIZES moderna Lilly GILEAD EQR REMAKING MEDICINE REGENERON Autolus gsk teva KODIAK BILL MELINDA CATES Foundation JENALI & NOVARTIS MERCK Ablynx A SANOFI COMPANY SANOFI Lyell + UNDISCLOSED PARTNERS including large cap pharmaceutical and biotechnology companies of all sizes Pfizer Invetx DARPA igmences#14BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 14 DIVERSE PORTFOLIO THAT ALREADY COVERS MOST THERAPEUTIC AREAS 138 + PROGRAMS UNDER CONTRACT therapeutic area KNOWN oncology allergic inflammation autoimmune diseases / women's health therapeutic area TBD / neuro-degeneration pain /ophthalmology 1 infectious disease / genitourinary system 1 cardiovascular#15BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 15 UNLOCK NEW TARGETS Our partners look to us to unlock new targets across a range of target types. For targets that have been selected by our partners, a third include challenging, high-value targets: 28% DIFFICULT targets 를 multi-pass transmembrane targets high homology targets 72% STANDARD targets & peptide-MHC targets#16BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 16 EMPOWER NEW MODALITIES FOR NEXT-GEN THERAPIES Our platform is an operating system designed to support many next-gen modalities, including: Y IgGs, IgMs, IgAs single chain antibodies CAR-T Cell therapies Y bispecific antibodies radioisotope conjugates CNS-delivered antibodies#17BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY COPYRIGHT © ABCELLERA 17 2 ANTIBODIES FOR COVID-19 There is an increase in the number of COVID-19 cases globally, with over 100,000 daily cases reported in the US alone. bamlanivimab + etesevimab Bamlanivimab alone and together with etesevimab has been used to treat more than 535,000 patients, potentially preventing 20,000+ hospitalizations and 10,000 deaths. Effective against Delta variant* bebtelovimab Currently in Phase 2 clinical trials alone and in combination with bamlanivimab and etesevimab. Effective against variants of concern, including the Delta variant* * Shown to be effective against the Delta variant in preclinical studies#1818 COPYRIGHT © ABCELLERA BANK OF AMERICA TECH SOLUTIONS FOR DRUG DISCOVERY ellera Nikon YOU THANK a